2 results
Approved WMOPending
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.
Approved WMORecruiting
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…